Universal Beteiligungs und Servicegesellschaft mbH Has $120.39 Million Stock Holdings in Edwards Lifesciences Corporation $EW

Universal Beteiligungs und Servicegesellschaft mbH raised its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 4.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,548,072 shares of the medical research company’s stock after acquiring an additional 63,850 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Edwards Lifesciences were worth $120,394,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of EW. Brighton Jones LLC bought a new position in Edwards Lifesciences in the 4th quarter valued at about $266,000. CX Institutional raised its holdings in shares of Edwards Lifesciences by 10.7% during the 2nd quarter. CX Institutional now owns 4,314 shares of the medical research company’s stock worth $337,000 after buying an additional 416 shares in the last quarter. Farther Finance Advisors LLC lifted its position in shares of Edwards Lifesciences by 24.4% during the 2nd quarter. Farther Finance Advisors LLC now owns 10,954 shares of the medical research company’s stock worth $857,000 after buying an additional 2,146 shares during the last quarter. Park Avenue Securities LLC acquired a new stake in Edwards Lifesciences in the second quarter valued at about $315,000. Finally, GAMMA Investing LLC boosted its stake in Edwards Lifesciences by 65.0% in the second quarter. GAMMA Investing LLC now owns 7,763 shares of the medical research company’s stock valued at $607,000 after buying an additional 3,059 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Stock Down 1.1%

Edwards Lifesciences stock opened at $83.40 on Wednesday. The firm has a market capitalization of $48.40 billion, a price-to-earnings ratio of 35.95, a price-to-earnings-growth ratio of 3.24 and a beta of 0.95. The firm’s fifty day moving average price is $85.09 and its two-hundred day moving average price is $80.69. Edwards Lifesciences Corporation has a 1-year low of $65.94 and a 1-year high of $87.89. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The firm had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period in the previous year, the company posted $0.67 EPS. The company’s revenue for the quarter was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, equities research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $85.70, for a total transaction of $87,328.30. Following the completion of the transaction, the vice president owned 22,002 shares in the company, valued at $1,885,571.40. This trade represents a 4.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of the stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $85.66, for a total value of $971,384.40. Following the sale, the vice president owned 31,870 shares in the company, valued at approximately $2,729,984.20. This represents a 26.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 57,824 shares of company stock valued at $4,863,323. Company insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Canaccord Genuity Group set a $87.00 price target on Edwards Lifesciences and gave the company a “hold” rating in a research note on Wednesday, December 17th. Cowen upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Friday, January 9th. JPMorgan Chase & Co. upgraded Edwards Lifesciences from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $90.00 to $100.00 in a report on Thursday, December 18th. Barclays reaffirmed an “overweight” rating and set a $104.00 price objective (up previously from $103.00) on shares of Edwards Lifesciences in a research report on Monday, January 12th. Finally, UBS Group reiterated a “neutral” rating and set a $95.00 target price (up previously from $92.00) on shares of Edwards Lifesciences in a research report on Monday, January 12th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $96.82.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.